5612 Results

People

  1. Giralt
    Giralt
  2. Ladanyi
    Ladanyi
  3. Arcila
    Arcila
  4. Perales
    Perales
  5. Drilon
    Drilon
  6. Hyman
    Hyman
  7. Berger
    Berger
  8. Solit
    Solit
  9. Motzer
    Motzer
  10. Reis-Filho
    Reis-Filho

Groups

  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)
  7. Center for Hematologic Malignancies (914)
  8. Survivorship Research (910)
  9. Department of Pathology and Laboratory Medicine (784)
  10. Population Sciences Research Program (751)
  1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
    Meeting Abstract

    Marth, C.; Vulsteke, C.; Rubio, M. J.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Radoslaw, M.; Ayhan, A.; Hasegawa, K.; Wu, X.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
    Meeting Abstract

    Hyman, D.; Hendifar, A.; Cheol Chung, H.; Maio, M.; Leary, A.; Spanggaard, I.; Rhee, J.; Marton, M.; Chen, M.; Krishnan, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
    Meeting Abstract

    George, D. J.; Casey, M.; Degtyarev, E.; Lechuga Frean, M. J.; Aimone, P.; Ravaud, A.; Halabi, S.; Motzer, R. J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M. D.; Gubens, M. A.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
    Meeting Abstract

    Friedlander, M. L.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models
    Meeting Abstract

    Fiascarelli, A.; Merlino, G.; Capano, S.; Paoli, A.; Bressan, A.; Bigioni, M.; Scaltriti, M.; Arribas, J.; Morales, C. B.; Pellacani, A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer
    Meeting Abstract

    Gartrell, B.; Del Priore, G.; Retter, A.; Chen, W. T.; Sokol, G. H.; Vandell, A.; Roach, M.; Scher, H. I.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data
    Meeting Abstract

    Ferrarotto, R.; Ho, A.; Wirth, L. J.; Muzaffar, J.; Rodriguez, C.; Dekel, E.; Walker, R. M.; Nadri-Shay, C.; Vergara-Silva, A.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
    Meeting Abstract

    Drilon, A.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V.; Camidge, R. D.; Stopatschinskaja, S.; Cui, J. J.; Hyman, D. M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save